Compare WETH & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | HOWL |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 17.9M |
| IPO Year | 2020 | 2021 |
| Metric | WETH | HOWL |
|---|---|---|
| Price | $1.09 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 134.8K | ★ 653.6K |
| Earning Date | 04-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.38 | ★ 18.40 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $45,136,818.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.82 | $0.27 |
| 52 Week High | $3.68 | $2.23 |
| Indicator | WETH | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 47.88 |
| Support Level | $0.95 | $0.35 |
| Resistance Level | $1.49 | $0.43 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 29.18 | 21.77 |
Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.